Buscar
Sarepta Therapeutics Inc
SRPTAñadir a la lista de seguimiento
14.860USD
-0.700-4.50%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.57BCap. mercado
23.85P/E TTM
Más Datos de Sarepta Therapeutics Inc Compañía
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Información de Sarepta Therapeutics Inc
Símbolo de cotizaciónSRPT
Nombre de la empresaSarepta Therapeutics Inc
Fecha de salida a bolsaJun 04, 1997
Director ejecutivoIngram (Douglas S)
Número de empleados1372
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 04
Dirección215 First Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono16172744000
Sitio Webhttps://www.sarepta.com/
Símbolo de cotizaciónSRPT
Fecha de salida a bolsaJun 04, 1997
Director ejecutivoIngram (Douglas S)
Ejecutivos de Sarepta Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.23M
+0.52%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
-138.12%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
54.56K
-263.23%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
48.41K
+34.86%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
42.10K
+40.09%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
38.20K
+44.57%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
31.22K
-492.36%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
11.52K
-1072.63%
Dr. M. Kathleen Behrens, Ph.D.
Dr. M. Kathleen Behrens, Ph.D.
Independent Chairwoman of the Board
Independent Chairwoman of the Board
--
--
Dr. Stephen L. Mayo, Ph.D.
Dr. Stephen L. Mayo, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.23M
+0.52%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
-138.12%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
54.56K
-263.23%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
48.41K
+34.86%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
42.10K
+40.09%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
38.20K
+44.57%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Sarepta Therapeutics Inc?
Los cinco principales accionistas de Sarepta Therapeutics Inc son: Mr. Richard J. (Rick) Barry
¿Cuántas instituciones poseen acciones de Sarepta Therapeutics Inc (SRPT)?
A fecha de 2026Q1, 1037 instituciones poseen acciones de Sarepta Therapeutics Inc, con un valor de mercado combinado de aproximadamente 95.57M, lo que representa el 90.53% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -25265811.00.
¿Cuál es la mayor fuente de ganancias de Sarepta Therapeutics Inc?
El 2026Q1, el segmento empresarial PMO Products generó la ganancia más alta para Sarepta Therapeutics Inc, ascendiendo a 965.57M y representando el 43.92% de la ganancia total.